help.medscape.com Sep 04
IgAN and the B Cell Pathway:
The therapeutic landscape for immunoglobulin A nephropathy (IgAN) is expanding rapidly, with agents targeting the B-cell pathway ...
medscape.org/advances/igan-bcell-2026a10006qi
Story Details
| Last Updated | |
| Total Articles | 2 |
Main Topics
More articles on this subject
Previous
help.medscape.com Sep 04
IgAN and the B Cell Pathway: The therapeutic landscape for immunoglobulin A nephropathy (IgAN) is expanding rapidly, with agents targeting the B-cell pathway ...
medscape.org/advances/igan-bcell-2026a10006qi
Next
Similar to This
Previous
help.medscape.com Oct 20
A New Era in Airway Disease Management: Advance your skills in managing and treating airway diseases with expert-led insights and clinical best practices.
medscape.org/advances/new-era-airway-disease-management-2025a1000j24
help.medscape.com Sep 24
Autoimmune Disorders: Is it time to switch? Learn to align therapeutic choices with individual patient characteristics to achieve truly patient-centric outcomes.
medscape.org/advances/neuromuscular-disorders-myasthenia-gravis-chronic-2026a1000cjv
help.medscape.com Sep 10
Optimizing Clinical Practice in Prostate Cancer: Keep up to date on the latest data in advanced prostate cancer and gain expert insights on their implications ...
medscape.org/advances/optimizing-clinical-practice-prostate-cancer-2026a1000jj9
help.medscape.com Jul 13
IgAN and the B Cell Pathway: The therapeutic landscape for immunoglobulin A nephropathy (IgAN) is expanding rapidly, with agents targeting the B-cell pathway ...
medscape.org/advances/igan-bcell-2026a10006qi
Why IBD 50's No. 2 Stock, Travere Therapeutics, Has Doubled In 2025: Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up ...
investors.com/research/the-new-america/travere-therapeutics-stock-kidney-disease-filspari-fsgs/
Next